6/28/23, 10:08 PM EXCEL Pathway Feedback Search Clinical Topics Home Studies EXCEL EXCEL Disease Coronary artery disease Trial question Is PCI with everolimus-eluting stents noninferior to bypass surgery in patients with left main coronary artery disease? Study design Multi-center Open label RCT Population Characteristics of study participants 23.0% female N = 1905 77.0% male 1905 patients (441 female, 1464 male) Inclusion criteria: patients with left main coronary artery disease who have low or intermediate anatomical complexity Key exclusion criteria: pregnancy, PCI of the left main trunk at any time prior to randomization, CABG at any time prior to randomization, noncardiac comorbidities with left expectancy < 3 years, SYNTAX score 33, Interventions N=948 PCI (PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents) N=957 CABG (standard surgical procedure) Primary outcome Death, stroke, or myocardial infarction at 3 years 15.4 15 4 % 14 7 https://web.pathway.md/studies/recGRKSalJ2WmCojy 1/2 6/28/23, 10:08 PM 15.4 % EXCEL Pathway 14.7 11.6 % 7.7 % Difference not exceeding nonferiority margin 3.9 % 0.0 % Percutaneous coronary intervention Coronary artery bypass graft Difference not exceeding nonferiority margin in death, stroke, or myocardial infarction at 3 years (15.4% vs. 14.7%; HR 1, 95% CI 0.79 to 1.26) Secondary outcomes Significant decrease in death, stroke, or myocardial infarction at 30 days (4.9% vs. 7.9%; MD -3.1, 95% CI -4.94 to -1.26) Safety outcomes Significant differences in major periprocedural adverse events within 30 days (12.4% vs. 44.0%, p < 0.001). Conclusion In patients with left main coronary artery disease who have low or intermediate anatomical complexity, PCI was noninferior to CABG with respect to death, stroke, or myocardial infarction at 3 years. Reference Stone GW, Sabik JF, Serruys PW et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016 Dec 8;375(23):2223-2235. Open reference URL https://web.pathway.md/studies/recGRKSalJ2WmCojy 2/2